Tioga Pharmaceuticals

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.